Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
One of the first lessons I learned in investing is to never blindly follow anyone, no matter how knowledgeable they appear to be and regardless of the strength of their track record. Everyone is wrong from time to time, even the best investors. In fact, if you hit on 7 out of 10 of your buys, that's actually a very good record; but that still leaves three duds/non-movers.
With that opening, I'm following portefeuille, zzlangerhans, and a handful of other top ranked Fools on this one. This is a "for fun" pick more than anything. Don't take it as a recommendation. In fact, as a deep value investor, I look at CRME's balance sheet and cash flows and I get scared off. However, CRME's balance sheet is not that atypical of a biotech outfit. Biotech is not normally the playground of value investors :)
In spite of that, I highly respect the opinions of port and ZZ and I still want to learn more about biotech/pharmas, so I figure this is a good stock to follow. It's also my type of high-risk/high-reward play.
Same here
Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study -> http://finance.yahoo.com/news/Cardiome-Announces-prnews-1641237433.html?x=0&.v=15.